CC chemokine receptor-2A is frequently overexpressed in glioblastoma.
Macrophages and monocytes migrate in response to chemotactic cytokines such as monocyte chemoattractant protein 1 (MCP-1/CCL2) in a variety of tissues including the central nervous system. Overexpression of MCP-1 has been reported in glioblastoma (GBM), which correlates to prominent macrophage infiltration characterized by this tumor type, but whether MCP-1 receptor is also expressed by the neoplastic cells remains unclear. Expression of MCP-1 and its receptor, CC chemokine receptor 2 (CCR2), were examined in GBM using cDNA microarrays and validated in two independent microarray datasets. We investigated the expression of the CCR2A isoform in human glioma cell lines and GBM, and found overexpression of CCR2A in most GBM specimens examined when compared to normal brain tissues. CCR2A is mainly localized in the cytoplasm of neoplastic cells, and pronounced neuronal cytoplasmic CCR2A immunoreactivity in tumor-infiltrating area was associated with prior chemo/radiation therapy. Glioma cells ectopically overexpressing CCR2A demonstrated increased migration compared to vector-transfected cells in vitro. Inhibition of MCP-1 synthesis suppressed migration of CCR2A-overexpressed glioma cells. Our data suggest that CCR2A might be associated with the pathobiology of GBM such as host response to treatment and tumor cell migration.
Liang
Yu
Y
Department of Neurological Surgery, Brain Tumor Research Center, University of California-San Francisco, San Francisco, CA 94143, USA. liangy01@hotmail.com
Bollen
Andrew W
AW
Gupta
Nalin
N
D001253:Astrocytes / Q000378:metabolism; D001921:Brain / Q000378:metabolism*; D001932:Brain Neoplasms / Q000235:genetics / Q000378:metabolism*; D016022:Case-Control Studies; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000235:genetics / Q000502:physiology; D018932:Chemokine CCL2 / Q000235:genetics / Q000378:metabolism*; D015972:Gene Expression Regulation, Neoplastic; D005909:Glioblastoma / Q000235:genetics / Q000378:metabolism*; D006801:Humans; D009837:Oligodendroglioma / Q000235:genetics / Q000378:metabolism; D020411:Oligonucleotide Array Sequence Analysis; D054390:Receptors, CCR2 / Q000235:genetics / Q000378:metabolism*; D012016:Reference Values
D018932:Chemokine CCL2; D054390:Receptors, CCR2
J Exp Med. 1997 Nov 17;186(10):1757-62
9362535
Cancer Res. 2005 Oct 1;65(19):8679-89
16204036
Cancer Res. 2002 May 15;62(10):2806-12
12019157
Semin Oncol. 2000 Jun;27(3 Suppl 6):1-10
10866344
Int J Cancer. 2004 Mar 20;109(2):214-9
14750172
Ann Neurol. 2003 Sep;54(3):388-92
12953273
BMC Genomics. 2003 Nov 25;4(1):46
14641910
J Neurochem. 2002 Apr;81(2):257-69
12064472
Cancer Res. 2003 Apr 15;63(8):1969-74
12702590
Nat Rev Neurosci. 2003 Jun;4(6):444-55
12778117
J Immunol. 2000 Nov 1;165(9):4877-83
11046012
Cancer Cell. 2006 Apr;9(4):287-300
16616334
Int J Cancer. 1994 Jul 15;58(2):240-7
7517920
Eur J Immunol. 1987 Sep;17(9):1271-8
3115791
Proc Natl Acad Sci U S A. 1997 Oct 28;94(22):12053-8
9342361
Semin Cancer Biol. 2004 Jun;14(3):149-54
15246049
Curr Opin Lipidol. 2001 Apr;12(2):175-80
11264989
Antisense Nucleic Acid Drug Dev. 2000 Jun;10(3):185-93
10905555
Acta Neuropathol. 2001 Oct;102(4):385-92
11603815
Curr Opin Oncol. 1997 May;9(3):215-22
9229142
Proc Natl Acad Sci U S A. 2005 Apr 19;102(16):5814-9
15827123
J Cell Biol. 1997 Nov 17;139(4):851-64
9362504
J Neurosci Res. 2002 Oct 15;70(2):219-31
12271471
Brain Res. 2001 Jun 1;902(2):171-7
11384610
J Clin Invest. 1997 Nov 15;100(10):2552-61
9366570
J Biol Chem. 1996 Aug 9;271(32):19084-92
8702581
Proc Natl Acad Sci U S A. 1994 Mar 29;91(7):2752-6
8146186
Cancer Res. 2001 Jul 1;61(13):4956-60
11431323
Brain Pathol. 2000 Jan;10(1):113-26
10668901
Acta Neuropathol. 1997 May;93(5):518-27
9144591
J Exp Med. 1998 Feb 16;187(4):601-8
9463410
Biochem Biophys Res Commun. 2002 Jan 11;290(1):73-80
11779135
Neuroscience. 2002;115(1):307-20
12401343